Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1998-4-23
|
pubmed:abstractText |
The multidrug resistance (MDR)-associated P-glycoprotein (P-gp) is a membrane transporter which carries, at the expense of MgATP hydrolysis, many amphiphilic molecules, such as the MDR-related cytotoxic drugs vincristine and vinblastine, and the MDR-reversing agents verapamil and progesterone. We have tested the effects on P-gp function of bromocriptine (BCT), an ergot alkaloid known as a D2 dopaminergic receptor agonist. BCT (at 4 microM) partially reverses the P-gp-mediated vincristine resistance of the Chinese hamster lung fibroblasts DC-3F/ADX, a MDR cell line. P-gp containing membrane vesicles prepared from the DC-3F/ADX cells exhibit, in the absence of any added drug, a basal MgATPase activity due to P-gp. BCT inhibits this basal ATPase activity, with a half-inhibiting concentration of 0.30 +/- 0.15 microM. BCT also inhibits the verapamil-induced P-gp ATPase stimulation competitively (Ki approximately 0.2 microM), and the progesterone-induced P-gp ATPase stimulation non-competitively (Ki approximately 0.07-0.10 microM). BCT also non-competitively inhibits the vinblastine-dependent P-gp ATPase activity within the same concentration range. Hydroxylated metabolites of BCT have different effects on P-gp ATPase, only the monohydroxylated being able to modulate both the basal and the drug-stimulated ATPase activities. In conclusion, these effects of BCT on P-gp function can be linked to a specific interaction with P-gp, probably involving inhibition of P-gp-mediated drug transport.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Bromocriptine,
http://linkedlifedata.com/resource/pubmed/chemical/Ca(2 ) Mg(2 )-ATPase,
http://linkedlifedata.com/resource/pubmed/chemical/Dopamine Agonists,
http://linkedlifedata.com/resource/pubmed/chemical/P-Glycoprotein,
http://linkedlifedata.com/resource/pubmed/chemical/Progesterone,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0006-291X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
17
|
pubmed:volume |
244
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
481-8
|
pubmed:dateRevised |
2005-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9514944-Animals,
pubmed-meshheading:9514944-Biological Transport, Active,
pubmed-meshheading:9514944-Bromocriptine,
pubmed-meshheading:9514944-Ca(2+) Mg(2+)-ATPase,
pubmed-meshheading:9514944-Cell Line, Transformed,
pubmed-meshheading:9514944-Cricetinae,
pubmed-meshheading:9514944-Dopamine Agonists,
pubmed-meshheading:9514944-Drug Resistance,
pubmed-meshheading:9514944-Drug Resistance, Multiple,
pubmed-meshheading:9514944-Hydroxylation,
pubmed-meshheading:9514944-Kinetics,
pubmed-meshheading:9514944-P-Glycoprotein,
pubmed-meshheading:9514944-Progesterone,
pubmed-meshheading:9514944-Vincristine
|
pubmed:year |
1998
|
pubmed:articleTitle |
Bromocriptine modulates P-glycoprotein function.
|
pubmed:affiliation |
Section de Biophysique des Protéines et des Membranes, DBCM, CEA, Centre d'Etudes de Saclay, Gif/Yvette, France. orlowski@dsvidf.cea.fr
|
pubmed:publicationType |
Journal Article
|